{
    "claims": [
        {
            "claim_id": "C01",
            "claim": "Intratumoral mRNA vaccination triggers a potent type I interferon response.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
                    "line_ref": "L42"
                },
                {
                    "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
                    "line_ref": "L31"
                }
            ],
            "caveat": "The observed effects were in murine models and may not directly translate to all human tumors."
        },
        {
            "claim_id": "C02",
            "claim": "The vaccine-induced inflammation improves antigen presentation on tumor cells.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Interferon-associated antigen processing and presentation pathways increase.",
                    "line_ref": "L43"
                },
                {
                    "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
                    "line_ref": "L28"
                }
            ],
            "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
        },
        {
            "claim_id": "C03",
            "claim": "mRNA vaccination sensitizes tumors to PD-L1 blockade.",
            "strength": "moderate",
            "evidence": [
                {
                    "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
                    "line_ref": "L45"
                },
                {
                    "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
                    "line_ref": "L32"
                }
            ],
            "caveat": "The human analysis is retrospective and non-randomized, limiting direct causal claims about sensitization."
        },
        {
            "claim_id": "C04",
            "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in patients receiving ICI.",
            "strength": "tentative",
            "evidence": [
                {
                    "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
                    "line_ref": "L30"
                },
                {
                    "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
                    "line_ref": "L46"
                }
            ],
            "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely. Vaccination timing and tumor heterogeneity are major limitations."
        }
    ]
}